Cytotoxicity as opposed to growth arrest was confirmed using outgrowth and bromodeoxyuridine-incorporation assays, along with propidium iodide staining in head and neck (HN5) and HER2+ breast cancer (BT474) cell line models. Here, ERBB2 is linked to breast carcinoma.